Myeloperoxidase -463 G/A polymorphism is associated with lung cancer risk: A meta-analysis with 7420 cases and 9132 controls.
Several studies evaluated the association between myeloperoxidase (MPO) -463 G/A polymorphism and the risk of lung cancer. However, the results were not stable. Online electronic databases (PubMed, EMBASE, and Wanfang database) were searched. The strength of association between the MPO -463 G/A polymorphism and lung cancer risk was assessed by calculating odds ratios (OR) with 95% confidence interval (CI). A total of 22 studies with 7420 cases and 9132 controls on the association between MPO -463 G/A polymorphism and lung cancer risk were included for this meta-analysis. MPO -463 G/A polymorphism was associated with a significantly decreased risk of lung cancer (OR = 0.91; 95% CI: 0.85-0.98; I 2 = 25%). In the race subgroup analysis, Asians with MPO -463 G/A polymorphism had decreased lung cancer risk (OR = 0.81; 95% CI: 0.70-0.93; I 2 = 0%). However, Caucasians did not show significant result (OR = 0.93; 95% CI: 0.86-1.02; I 2 = 36%). In the subgroup analysis according to source of control, both population-based studies and hospital-based studies were marginally significantly associated with decreased risk of lung cancer (OR = 0.90; 95% CI: 0.82-1.00; I 2 = 41% and OR = 0.91; 95% CI: 0.82-1.01; I 2 = 0%). The present meta-analysis suggested that the MPO -463 G/A polymorphism carriers had a protective role in lung cancer.